Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients

Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients : a Prognostic Observational Retrospective Monocentre Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05458752

Acronym

PnP-HIV-Free

Enrollment

133

Registered

2022-07-14

Start date

2020-04-01

Completion date

2023-07-01

Last updated

2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumocystis Jirovecii Infection

Keywords

pneumocystis jirovecii pneumonia, HIV-free patients

Brief summary

Pneumocystis jirovecii pneumonia (PjP) is a rare infectiouse disease with a high level of mortality. PjP is a classical opportunistic infection which concern HIV infected and immunocompromised patients. During the past decade, several therapeutic's progresses have been done in oncology, immunology and hematology. As a consequence, patients benefited of greater treatment efficacy but are exposed to a higher risk of opportunistic infections as PjP. The investigators hypothesis is that PjP incidence increase and its form is depending of underlying immune conditions. The investigators aim to describe its incidence, the PjP forms depending on comorbidities and to identifiy pronostics factors.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Underlying immune condition at risk of Pneumocystis jirovecii pneumonia excluding HIV infection * Clinical, biological and radiological presentation which evoke Pneumocystis jirovecii pneumonia * Microbiological confirmation by respiratory specimen analyses ( specific coloration and/or IFI and/or PRC)

Exclusion criteria

* No microbiological confirmation by respiratory specimen analyses * Proved HIV infection * Patient denied to particpate

Design outcomes

Primary

Measure	Time frame	Description
Incidence of Pneumocystis jirovecii pneumonia in HIV-free patients	Between the first january 2004 and the 31th december 2021	Number of cases / number of patients treated for a predisposing disease (heamotological or imunological disease, or cancer...)

Secondary

Measure	Time frame	Description
To describe the body mass index of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	BMI in kg/m2 (quanti
To describe the Charlson comorbidity index of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	Charlson comorbidity index as a quantitative variable
To describe the comoribidites of HIV-free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	Comorbidities as categorial variables
To describe the previous medications used by HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	Medications as categorial variables
To describe clinical features of Pneumocystis jirovecci pneumonia in HIV-free patients	Between the first january 2004 and the 31th december 2021	Type of first symptoms as categorial variables
To describe the date of the first symptoms of Pneumocystis jirovecci pneumonia in HIV-free patients	Between the first january 2004 and the 31th december 2021	Date of first symptoms as quantitative variable
To describe the pO2 level of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	pO2 (in mmHg)
To describe the PCR level of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	PCR (mg/L)
To describe the WBC level of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	WBC (G/L)
To describe the creatinine level of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	Creatinine (µmol/L)
To describe the LDH level of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	LDH (MUI/L)
To describe the albumin level of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	albumin (g/L)
To describe the age of giv free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	age in years
To describe the lymphocytes level of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	lymphocytes (G/L)
To describe the PCR pneumocystis level of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	PCR pneumocystis in ct
To describe the immunofluorescence value of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	Immunofluorescence as a categorial variable
To describe the specific coloration value of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	Specific coloration as a categorial variable
To describe the use of nasal canula in HIV free patient with a Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	Nasal canula as a categorial variable
To describe the use of high flow oxygenation in HIV free patient with a Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	High flow oxygenation as a categorial variable
To describe the use of mechanical ventilation in HIV free patient with a Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	Mechanical ventilation as a categorial variable
To describe the duration of hospitalisation of HIV free patients with Pneumocystis carinii pneumonia	Between the first january 2004 and the 31th december 2021	Duration in days
To describe the use of cotrimoxazole for HIV free patients with Pneumocystis carinii pneumonia	Between the first january 2004 and the 31th december 2021	cotrimoxazole as a categorial variable
To describe the use of atovaquone for HIV free patients with Pneumocystis carinii pneumonia	Between the first january 2004 and the 31th december 2021	atovaquone as a categorial variable
To describe the use of pentamidine for HIV free patients with Pneumocystis carinii pneumonia	Between the first january 2004 and the 31th december 2021	pentamidine as a categorial variable
To describe the use of steroïd for HIV free patients with Pneumocystis carinii pneumonia	Between the first january 2004 and the 31th december 2021	steroïd as a categorial variable
To describe the immunoglobulin level of HIV free patients with Pneumocystis jirovecci pneumonia	Between the first january 2004 and the 31th december 2021	immunoglobulin (g/L)

Countries

France

Outcome results